Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



‘Liquid biopsy’ guides PARP inhibitor treatment of prostate cancer

Analysis of circulating free tumour DNA in blood shows how well cancer therapy is working and can inform further treatment.

Metastatic prostate cancer is the second largest cause of cancer-related death in men, yet there are currently no predictive biomarkers to guide treatment.

In a phase II trial published in Cancer Discovery[1] (online, 27 April 2017), researchers analysed data on circulating free tumour DNA (cfDNA) in blood samples from men with advanced prostate cancer who received the PARP inhibitor, olaparib, in a clinical trial.

They found that after eight weeks of treatment, cfDNA levels dropped by around half in men who responded to the drug and increased slightly in non-responders. They were also able to detect all the genetic mutations predictive of response to PARP inhibitors in cfDNA as well as secondary mutations that arose at disease progression.

The researchers say that so-called ‘liquid biopsies’ could be used to predict prognosis, determine response and detect emerging resistance in metastatic prostate cancer.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203090

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Micrograph of adenocarcinoma in the prostate

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.